The CED (Committee to Evaluate Drugs) recommended that isopropyl myristate (Resultz®) be listed as General Benefit on the Ontario Drug Benefit (ODB) Formulary on the basis that isopropyl myristate (Resultz®) is safer and more effective than the currently funded alternatives.